Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)

Annals of the Rheumatic Diseases

Volumn 73, Issue 9, 2014, Pages 1689-1694

  Kavanaugh, Arthur ^a   McInnes, Iain B ^b   Mease, Philip ^c   Krueger, Gerald G ^d   Gladman, Dafna ^e   Van Der Heijde, Désirée ^f   Zhou, Yiying ^g   Lu, Jiandong ^g   Leu, Jocelyn H ^g   Goldstein, Neil ^g   Beutler, Anna ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CORTICOSTEROID; DRUG ANTIBODY; GOLIMUMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ABSCESS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMERICAN COLLEGE OF RHEUMATOLOGY 20 RESPONSE CRITERIA; ARTHRITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; BILIRUBIN BLOOD LEVEL; BLADDER CANCER; BODY SURFACE; BONE RADIOGRAPHY; BREAST CANCER; CARDIOVASCULAR DISEASE; CELLULITIS; CHOLELITHIASIS; COLON CANCER; CONGESTIVE CARDIOMYOPATHY; DAS28; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; ESOPHAGUS CANCER; HEALTH ASSESSMENT QUESTIONNAIRE; HEART INFARCTION; HEART VENTRICLE FAILURE; HERPES ZOSTER OPHTHALMICUS; HISTOPLASMOSIS; HUMAN; INJECTION SITE REACTION; INTERVERTEBRAL DISK DEGENERATION; LEGIONNAIRE DISEASE; LUNG SMALL CELL CANCER; LUNG TUBERCULOSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON MELANOMA SKIN CANCER; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHARP VAN DER HEIJDE SCORE; SHORT FORM 36; SIDE EFFECT; SKIN CARCINOMA; SUPERFICIAL THROMBOPHLEBITIS; THORAX PAIN; TIBIA FRACTURE; TOXOPLASMOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84905083653     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204902     Document Type: Article

References (11)

1. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36. (Pubitemid 40530131)
2. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008;35:869-76. (Pubitemid 351747130)
3. Mease PJ, Gladman DD, Ritchlin CT, et al.; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89. (Pubitemid 41447111)
4. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000;356:385-90. (Pubitemid 30487495)
5. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72. (Pubitemid 38924405)
6. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86. Erratum in: Arthritis Rheum 2010;62:2555.
7. Kavanaugh A, van der Heijde D, McInnes I, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012;64:2504-17.
8. Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013;72:1777-85.
9. Mease PJ, Ganguly R, Wanke L, et al. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Abstract presented at EULAR 2004. Ann Rheum Dis 2004;63(Suppl 1):391-2.
10. National Cancer Institute. The Surveillance, Epidemiology, and End Results (SEER) Database. 2004. http://seer.cancer.gov/statistics (accessed 22 Jul 2013).
11. Agency for Healthcare Research and Quality (US). Comparative effectiveness review summary guides for clinicians. 20 November 2012. http://www.effectivehealthcare.ahrq.gov/ehc/products/464/1045/ CER54-PsoriaticArthritisDrugTherapies-FinalReport-20120601.pdf (accessed 22 Jul 2013).